What eXoZymes (EXOZ) Said on Its Q3 Earnings Call

eXoZymes (NASDAQ:EXOZ) is working to scale up its lead dietary supplement ingredient, Tyferyn, while targeting a safety determination in the second quarter of 2027 and a human pharmacokinetic study in the first quarter, executives said during the company’s third-quarter 2026 investor update.

The company selected Curia Global in September as its commercial-scale manufacturing partner for Tyferyn, previously known as NCT. Technology transfer began in the fourth quarter, with the companies working toward larger-scale production in 2027.

eXoZymes reported a third-quarter net loss of $2.24 million, or $0.24 per share, compared with a loss of $2.29 million, or $0.27 per share, a year earlier. VP of Finance Fouad Nawaz said the narrower net loss reflected a $0.77 million noncash gain from a change in the fair value of warrant liabilities; the company’s operating loss increased.

Manufacturing and launch plans

Chief Commercial Officer Damien Perriman said Curia will handle the full manufacturing process, including enzyme fermentation in León, Spain, and the cell-free reaction and purification in Rozzano, Italy. eXoZymes does not plan to build its own manufacturing facilities, he said.

The company intends to market Tyferyn as a dietary supplement ingredient and is considering ingredient sales to supplement brands, a direct-to-consumer brand and marketing alliances. Perriman said the structure of any partnership or spin-out has not been determined.

The launch timeline depends on Curia completing scale-up and technology transfer, eXoZymes securing a marketing launch partner and regulatory requirements in the markets where the product will be sold, Perriman said. The company has not yet secured a launch partner.

For market entry, eXoZymes is targeting a self-affirmed determination that the ingredient is generally recognized as safe, or GRAS, supported by an independent expert panel. Perriman said the company is watching an FDA proposed rule that would require notification of future GRAS determinations; if finalized, it could change the company’s regulatory path and timeline.

The planned single-dose, IND-exempt study in healthy adults is intended to assess absorption and help set a dose for future studies. Perriman said product claims would be limited to structure-function statements, with no disease claims.

Process development and research

Chief Scientific Officer Tyler Korman said NCT is a rare plant compound found in black peppercorns and other plants. The company’s platform uses engineered enzymes outside living cells to convert feedstock into target molecules.

In a January pilot, independent partner Cayman Chemical ran eXoZymes’ patent-pending NCT process in a 100-liter reactor, producing 535 grams of NCT at 99.6% purity, Korman said. He said subsequent process changes increased output per liter by approximately 67% and made the reaction roughly five times faster.

Those changes could increase productivity approximately tenfold compared with the pilot process, Korman said, but he stressed that the figure is an internal estimate and has not been demonstrated at commercial scale.

Korman cited a published third-party study in mice and two small, short human studies that used a blend of NCT and a related molecule, NFT. He cautioned that eXoZymes did not conduct those studies and that the human results may not predict results with the company’s pure NCT product. The operator noted that statements about Tyferyn have not been evaluated by the FDA and that the product is not intended to diagnose, treat, cure or prevent disease.

Beyond Tyferyn, Korman said the company’s supplement program for joint comfort has completed proof of concept and begun scale-up, while a program targeting mental stress, focus and energy has completed proof of concept. Its pharmaceutical analog candidates remain in discovery or lead optimization, with none yet in IND-enabling studies or clinical trials.

Spending and liquidity

Third-quarter operating costs rose to $3.05 million from $2.52 million a year earlier. Research and development costs, net of grant reimbursements, increased to $1.62 million from $1.22 million, while general and administrative costs rose to $1.43 million from $1.31 million.

For the first nine months of 2026, the net loss widened to $7.49 million from $6.5 million, and cash used in operating activities rose to $5.39 million from $4.53 million. Nawaz said the company ended September with $3.26 million in cash and cash equivalents, which it expects to support operations and key initiatives into the beginning of 2027.

CEO Michael Heltzen said eXoZymes filed a registration statement on Form S-1 that had not yet become effective. Because the company was in registration, executives did not discuss the proposed offering or hold a question-and-answer session.

About eXoZymes (NASDAQ:EXOZ)

eXoZymes is a biotechnology company focused on cell-free biomanufacturing. Its approach uses enzymes outside living cells to produce compounds, offering an alternative to conventional manufacturing methods. The company’s work centers on developing its biomanufacturing platform and applying it to the production of useful molecules. Publicly available information about specific commercial products, customer markets, geographic reach and company leadership is limited.